Abstract
Sickle cell disease is a burdensome disease with limited treatment options. Given how inconclusive the evidence is for some of the newer agents, clinicians seem to only have hydroxyurea and crizanlizumab as treatment options for preventing vaso-occlusive events in patients with SCD.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
